Ocular Therapeutix Inc., of Bedford, Mass., said underwriters of its initial public offering (IPO) exercised in full their overallotment option to purchase an additional 750,000 shares at the IPO price of $13 per share. In total, the firm sold about 5.8 million shares, resulting in gross proceeds of about $74.8 million and net proceeds of about $66.5 million, which will be used to support three clinical programs, including phase III trials of the company's lead candidate, a dexamethasone-eluting plug for the treatment of ocular inflammation and pain following cataract surgery. (See BioWorld Today, July 28, 2014.)